The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2026 | UVI5008: a dual-action BTK epi-Inhibitor for resistant B-cell malignancies
Carmela Dell’Aversana, PhD, LUM University, Bari, Italy, discusses UVI5008, a first-in-class reversible, non-covalent BTK epi-inhibitor for B-cell malignancies. She explains its dual mechanism of action, combining direct BTK inhibition with epigenetic suppression of BTK expression, and highlights its potential activity in patients with resistance-associated C481S mutations. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
